Overview of Dr. Reidy
Dr. Diane Reidy is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 17 years. She is one of 62 doctors at NYC Health + Hospitals / Bellevue and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.
Office
1275 York Ave Dept Of
Box #8, Mskcc
New York, NY 10065Fax+1 212-639-2283
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2005
State University of New York Downstate Medical Center College of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2002 - 2026
NJ State Medical License 2020 - 2025
OK State Medical License 2020 - 2021- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors Start of enrollment: 2008 Aug 01
- Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Feb 01
- Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Start of enrollment: 2010 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 116 citationsA precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.Mariano J. Alvarez, Prem S. Subramaniam, Laura H. Tang, Adina Grunn, Mahalaxmi Aburi
Nature Genetics. 2018-06-18 - 57 citationsPhase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil, Bryan Bienvenu, W. Graydon Harker
Clinical Colorectal Cancer. 2012-06-01 - 195 citationsAppropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.Thomas A. Hope, Emily K. Bergsland, Murat Bozkurt, Michael M. Graham, Anthony P. Heaney
Journal of Nuclear Medicine. 2018-01-01
Journal Articles
- Biodistribution and Radiation Dose Estimates for 68Ga-DOTA-JR11 in Patients with Metastatic Neuroendocrine TumorsSimone Krebs, Lisa Bodei, Diane Reidy, Bradley J Beattie, Wolfgang A Weber, European Journal of Nuclear Medicine and Molecular Imaging
Authored Content
- Gene Signature Associated with Upregulation of the Wnt/Β-catenin Signaling Pathway Predicts Tumor Response to Transarterial EmbolizationMarch 2018
Press Mentions
The Pandemic Is Leading to Missed Cancer Diagnoses, New Data WarnsDecember 17th, 2021- Westchester Healthcare Matures During the Coronavirus PandemicMay 26th, 2020
Ipsen : Neuroendocrine Tumor (NET) Expert CallMay 3rd, 2018- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
